Astra gives in vivo Car-T its biggest endorsement
The company buys Belgium’s EsoBiotec for $425m.
The company buys Belgium’s EsoBiotec for $425m.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
Party season approaches; but first, conferences.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.